Combusted tobacco use continues to devastate public health in the United States and worldwide. The Tobacco Control Act provides the Food and Drug Administration with the authority to establish product standards for the nicotine content of combusted tobacco products. In this renewal application we address a critical question: What will be the impact of reducing nicotine in cigarettes in the context of alternative tobacco products? If reduced nicotine product standards render combusted tobacco products less reinforcing, smokers who choose not to quit using nicotine/tobacco completely will likely increase their use of non- combusted products. This shift from combusted to non-combusted products could greatly reduce toxicant exposure and reduce the harms associated with tobacco. Three Projects and 3 Cores are proposed. Project 1 (PI: Hatsukami) is a 12-week clinical trial that examines the use of very low nicotine content (VLNC) vs. normal nicotine content (NNC) cigarettes when smokers are provided vouchers to exchange for cigarettes in an experimental marketplace that contains a wide range of non-combusted products. Project 2 (PI: Donny) is a 7- week clinical trial comparing VLNC and NNC cigarettes when participants have access to electronic cigarettes that vary in nicotine concentration (high v. low) and available flavors (tobacco only v. tobacco and other flavors). Project 3 (PIs: Colby & Tidey) is a laboratory-based study that assessed the choice to smoke, vape, or abstain when adolescent smokers are provided cigarettes with VLNC v. NNC and e-cigarettes that vary in nicotine concentrations and flavors. The Cores will provide the infrastructure and resources to conduct these studies. The Administrative Core (Directors: Donny & Hatsukami) will ensure the implementation of appropriate procedures and protocols, the integration of methods, measures, and concepts, the communication and dissemination of information, the generation of new tobacco regulatory science through a pilot project program, and the training of new tobacco regulatory scientists. The Biomarkers Core (Director: Hecht) will provide analysis of biomarkers associated with exposure to nicotine and tobacco-related toxicants. The Biostatistics and Data Management Core (Director: Le) will assist in study design, integration and monitoring of data, data analysis, and, when appropriate, the development of novel ways to analyze data.
OVERALL NARRATIVE Product standards that reduce the nicotine content of combusted tobacco products could reduce the devastating public health effects of tobacco by rendering cigarettes and similar products less addictive. This application proposes three projects aimed at determining the impact of reducing nicotine in cigarettes in the context of the availability of non-combusted products that might influence smoking behavior.
|Villanti, Andrea C; Gaalema, Diann E; Tidey, Jennifer W et al. (2018) Co-occurring vulnerabilities and menthol use in U.S. young adult cigarette smokers: Findings from Wave 1 of the PATH Study, 2013-2014. Prev Med 117:43-51|
|Pericot-Valverde, Irene; Elliott, Rebecca J; Miller, Mollie E et al. (2018) Posttraumatic stress disorder and tobacco use: A systematic review and meta-analysis. Addict Behav 84:238-247|
|Denlinger-Apte, Rachel L; Tidey, Jennifer W; Koopmeiners, Joseph S et al. (2018) Correlates of support for a nicotine-reduction policy in smokers with 6-week exposure to very low nicotine cigarettes. Tob Control :|
|Parker, Maria A; Streck, Joanna M; Bergeria, Cecilia L et al. (2018) Reduced Nicotine Content Cigarettes and Cannabis Use in Vulnerable Populations. Tob Regul Sci 4:84-91|
|Kazi, Abid; Fazzi, Alyse; Krebs, Nicolle M et al. (2018) Cigarette Management System: An operating procedures guide to obtaining and managing investigational tobacco products for regulatory science research. Contemp Clin Trials Commun 11:69-74|
|Hatsukami, Dorothy K; Luo, Xianghua; Jensen, Joni A et al. (2018) Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial. JAMA 320:880-891|
|Boatman, Jeffrey A; Vock, David M; Koopmeiners, Joseph S et al. (2018) Estimating causal effects from a randomized clinical trial when noncompliance is measured with error. Biostatistics 19:103-118|
|Hatsukami, Dorothy K; Donny, Eric C (2018) The Debate About Nicotine Addiction and the Role of Medicinal Products: Commentary on Zeller. Nicotine Tob Res :|
|Smith, Tracy T; Hatsukami, Dorothy K; Benowitz, Neal L et al. (2018) Whether to push or pull? Nicotine reduction and non-combusted alternatives - Two strategies for reducing smoking and improving public health. Prev Med 117:8-14|
|Dermody, Sarah S; McClernon, F Joseph; Benowitz, Neal et al. (2018) Effects of reduced nicotine content cigarettes on individual withdrawal symptoms over time and during abstinence. Exp Clin Psychopharmacol 26:223-232|
Showing the most recent 10 out of 63 publications